Objective: Brivaracetam (BRV) and levetiracetam (LEV) are effective antiepileptic drugs that bind selectively to the synaptic vesicle 2A (SV2A) protein. However, BRV differs from LEV in that it exhibits more potent and complete seizure suppression in animal models including in amygdala-kindled mice, where BRV afforded nearly complete seizure suppression. This raises the possibility that aside from potency differences, BRV and LEV may interact differently with the SV2A protein, which is not apparent in radioligand-binding competition studies. In this study, we used a recently identified SV2A allosteric modulator, UCB1244283, that appears to induce conformational changes in SV2A, to probe the binding properties of labeled BRV and LEV. The synaptic vesicle 2A (SV2A) protein is an integral transmembrane glycoprotein expressed in neurons and endocrine cells, where it specifically localizes to secretory vesicles.
The synaptic vesicle 2A (SV2A) protein is an integral transmembrane glycoprotein expressed in neurons and endocrine cells, where it specifically localizes to secretory vesicles. 1, 2 It is notable that the SV2A protein was shown to bind the antiepileptic drugs (AEDs) levetiracetam 3 (LEV) and brivaracetam 4 (BRV), and was also shown to be the molecular target of their anticonvulsant activity. 5 A strong positive correlation has been demonstrated between anticonvulsant potency in animal models and SV2A binding affinity, [4] [5] [6] and seizure protection correlates with SV2A occupancy. 4 In addition, the anticonvulsant activity of LEV is reduced in SV2A-deficient animals. 6 It has also been shown that LEV reverses the synaptic deficits produced by overexpression of the SV2A protein. 7 These data suggest that the incidence of seizures are affected by both increased and decreased expression of SV2A and are reduced by treatment with LEV. Although there is good evidence suggesting that the SV2A protein is the molecular target of action for the antiepileptic drugs BRV and LEV, little is known about the precise function of the SV2A protein or how these drugs may affect SV2A function.
A recent review concluded that, although the SV2A protein is involved in normal synaptic vesicle function, its precise role remains unclear. 8 Experimental evidence suggests that the SV2A protein has a role in either regulating synaptic exocytosis or as a vesicular transporter. Different studies have shown that SV2A regulates neurotransmitter release, although the mechanism remains unknown. Studies of cultured neurons from SV2A knockout mice show a reduced postsynaptic response due to a lower initial vesicle release probability, 9 and a decrease in the total amount of neurotransmitter released during a stimulation. 10 This reduced release probability occurs after vesicle docking and before formation of the SNARE (soluble N-ethylmaleimidesensitive fusion) complex, suggesting that SV2A contributes to the priming of vesicles for release. 11 Changes in SV2A expression have been shown to alter glutamatergic and c-aminobutyric acid (GABA)ergic transmission; consequently, in hippocampal slices from SV2A-and SV2A/B-knockout mice, the frequency and amplitude of spontaneous inhibitory postsynaptic currents (IPSCs) were decreased, without changes in mini-IPSCs. 12 In contrast, the spontaneous excitatory postsynaptic currents (EPSCs) were increased, suggesting an effect on glutamate release. To characterize the effect of LEV on neurotransmitter release, the effects of LEV on synaptic vesicle loading and unloading and on whole-cell patch recording were studied. 13, 14 These results suggest that LEV reduces neurotransmitter release, but in a time-and stimulation-dependent manner, and offer support for the theory that LEV may enter neurons via vesicle recycling and reduce neurotransmitter release during periods of high-frequency activity. 13, 14 The SV2A protein has 12 transmembrane domains, and the protein sequence is related to a family of bacterial proteins that transport sugars, citrate, and drugs-the major facilitator superfamily (MFS). 1 Therefore, SV2A may function as a transporter, although little evidence supports this, apart from the finding that the SV2A protein acts as the point of entry of botulinum neurotoxin E into neurons. 15 However, it has recently been shown that, in hexosetransport deficient yeast, the human SV2A protein acts as a galactose transporter. 16 This finding could have important implications if extended to mammalian cells. If the SV2A protein is a member of the MFS family, then it should act as a transporter via the alternating access mechanism. 17 We have recently identified UCB1244283 ((4-(3,5-dimethylphenyl)-N-(2-methoxyphenyl)-3-methylbutanamide) as an allosteric modulator that can modulate the conformation of the SV2A protein and which had a differential effect on the binding interaction of LEV and a LEV analogue ([ 3 H] UCB30889). 18 BRV, an SV2A ligand that was developed to have a high affinity for SV2A, differs from LEV in that it exhibits more potent and complete seizure suppression in several different animal models (e.g., it exerts more persistent effects against kindling acquisition). 19, 20 
Membrane preparations
Human SV2A was cloned from a fetal brain complementary DNA (cDNA) library as described previously, 5 and stably expressed in human embryonic kidney (HEK) cells. Cells were subcultured in Dulbecco's modified Eagle's medium (DMEM) containing 200 mM of L-glutamine and 100 lg/ml zeocin, supplemented with 10% fetal bovine serum. The cells were grown in a humidified atmosphere of 5% CO 2 at 37°C. Confluent cells were harvested by trypsinization and pelleted by centrifugation at 1,500 g for
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• An SV2A modulator increased the binding of both LEV and BRV radioligands, but this effect was shown to be due to different mechanisms • Pharmacologic differences between BRV and LEV may be due to differences in their interaction with the SV2A protein 10 min at 4°C. The pellet was washed once with ice-cold phosphate-buffered saline (PBS) using the same centrifugation protocol. The resulting pellet was homogenized in a buffer containing 15 mM Tris-HCl, 1 mM ethylene glycol tetraacetic acid (EGTA), 0.3 mM ethylene diamine tetraacetic acid (EDTA), and 2 mM MgCl 2 (pH 7.5) supplemented with complete protease inhibitor cocktail (Roche, Vilvoorde, Belgium). The homogenate was freeze-thawed twice and equilibrated at 25°C followed by a 10-min DNAse (10 U/ ml) treatment. Subsequently, the solution was centrifuged for 25 min at 40,000 g and 4°C. Finally, the pellet was resuspended in 20 mM Tris-HCl buffer (pH 7.4) containing 250 mM of sucrose (buffer A) at a protein concentration of 5-10 mg/ml and stored in liquid nitrogen.
Membrane preparations from human brain were prepared at 4°C with all homogenization steps preformed in a biologic safety cabinet. The tissues were homogenized (10% w/ v) in buffer A. The homogenates were spun at 30,000 g for 15 min, and the pellets were resuspended in the same buffer. After incubation at 37°C for 15 min, the membranes were washed three times using the same centrifugation protocol. The final pellets were resuspended in buffer A at a protein concentration of 10-15 mg/ml and stored in liquid nitrogen.
Radioligand binding studies
Experiments were performed as described previously.
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For all assays, membrane proteins (5-25 lg/assay for HEK293 SV2A membranes; 150-200 lg/assay for human brain) were incubated for 120 min at 4°C in 0.2 ml of 50 mM Tris-HCl buffer (pH 7.4) containing 2 mM MgCl 2 .
Kinetic experiments
Specific binding in association experiments was measured at differing times after addition of the membrane proteins at 4°C. Membranes were preincubated for 30 min with 30 lM of UCB1244283 or buffer control prior to initiation of the experiment. The reaction was started by the addition of radioligand; [ 3 H]LEV was diluted with cold ligand to a final concentration of 200 nM and [ 3 H]BRV was diluted with cold ligand to a final concentration of 4-5 nM (these concentrations were chosen to be below the K d of the ligand and give a good assay window). Dissociation was induced by addition of LEV (10 mM) to the association reaction mixture at the indicated times. Samples were filtered on GF/C glass fiber filters presoaked in 0.1% polyethylenimine (PEI) and washed with 5 ml of ice-cold Tris-HCl buffer (50 mM, pH 7.4). The total filtration time per sample did not exceed 2 s. In the association experiments, K obs is the observed rate constant and is equal to K on *L + K off (where K on : association rate constant; K off : dissociation rate constant; L: radioligand concentration).
Saturation binding studies
Membrane proteins were incubated for 120 min with radioligand concentrations of 0.08-10 lM for [
3 H]LEV and 0.02-2 lM for [ 3 H]BRV, with samples prepared from a single stock that was isotopically diluted with cold ligand. Samples were filtered on GF/B filters using a Brandel harvester. The total filtration time did not exceed 10 s.
In all experiments, nonspecific binding (NSB) was defined as the residual binding observed in the presence of 10 mM of LEV. Radioactivity was determined by liquid scintillation.
Data analysis
Data analysis was performed by computerized nonlinear curve-fitting methods (GraphPad Prism 5 software, San Diego, CA, U.S.A.) according to equations describing several binding models. 23 Half maximal inhibitory concentration (IC 50 ) values were corrected to inhibitory affinity constant (K i ) values by applying the Cheng-Prusoff equation. 24 Comparisons between different curve fits were carried out using an extra-sum-of-squares F-test and the decision level was set at 0.05. The curve fits on the graphs represent the predicted values of the best fit. Unpaired Student's t-test was used to compare two groups of data.
Results

Saturation-binding studies in membranes from HEK293/SV2A cells
In preliminary experiments, the SV2A modulator UCB1244283 increased the binding of [ 3 H]LEV and [ 3 H] BRV in a concentration-dependent manner (Fig. 1) . A concentration of 30 lM was used in all further studies, as this caused a near-maximal effect in the absence of solubility issues.
Due to the previously reported affinities of the ligands for the SV2A protein and the specific activity of the radioligands, the labeled radioligand was diluted with unlabeled compound to form a stock solution, and serial dilutions were prepared from this stock. Under these conditions and with a 2-h incubation at 4°C, [ Table 1 and Fig. 2 ). In the presence of the SV2A modulator, there was a two-to threefold increase in affinity for [ 3 H] LEV, with a twofold increase in the apparent binding capacity (Table 1 ; Fig. 2A Fig. 2B ). In the presence of the SV2A modulator, there was a marked 10-fold increase in apparent affinity for [ 3 H]BRV and a smaller 1.4-fold increase in binding capacity.
Saturation-binding studies in membranes from human brain tissue
The studies described earlier were performed in a cell line overexpressing the human SV2A protein. It was important to determine whether these effects were maintained in native tissue with a physiologic expression of the protein. We therefore performed similar saturation studies in membranes prepared from human brain tissue (cortex and hippocampus). There were no significant differences between cortical (n = 3) or hippocampal (n = 2) tissue so data were pooled. There was variability in the absolute values of binding levels (B max ) seen across tissues, so experiments were performed pairwise (i.e., saturations for both radioligands in the presence and absence of modulator were performed at the same time on each batch of tissue), and B max values were normalized to the Kinetic-binding studies in membranes from HEK293/ SV2A cells Kinetic experiments were conducted to determine if the changes in affinity were reflected in changes in the association and dissociation rates of the radioligands for the SV2A protein. The specific binding of [ 3 H]LEV to the HEK 293/SV2A membranes reached equilibrium within 120 min and was reversible. Both association and dissociation rates were best described by a two-phase model as summarized in Table 3 . Of interest, the presence of the modulator did not have a profound effect on any of the [ 3 H]LEV kinetic parameters, as shown in Figure 3A , in which the modulator appears to only increase the signal size.
The specific binding of [ 3 H]BRV to the HEK293/SV2A membranes also reached equilibrium in 120 min, was reversible, and was best described by a two-phase model (Table 3) . However, in the presence of the modulator, equilibrium was not reached within 120 min, with a considerable slowing of both the association and dissociation of [ (Fig. 3B) , and association rates were best described by a one-phase model (Fig. 3B) . However, dissociation rates, both in the absence and presence of the modulator, were best described by a two-phase model with a slowing in both kinetic off-rates (Table 3) .
Discussion
LEV was developed as an effective treatment for epilepsy based largely on its activity in animal models of epilepsy, independent of its mechanism of action (the latter being unknown at the time of approval). Following the identification of the SV2A protein as the likely molecular target of its therapeutic action, 5 the more potent and selective analogue, BRV, was identified. 4, 20, 25, 26 Although BRV can be viewed as a more potent and selective version of LEV, in animal models it is seen as being different from LEV in that it gives a more potent and complete seizure suppression across a wider number of animal models. 20 We In saturation studies in membranes prepared from HEK293 cells expressing the human SV2A protein, both [ ]BRV was largely due to an increase in affinity (ninefold) and a small increase in B max (1.3-fold). It was important to see if the differential effects of the modulator were maintained in a more physiologic situation (i.e., a non-recombinant expression system). Therefore, human brain tissue was examined, which contains endogenous SV2A protein expressed in the appropriate compartment (i.e., synaptic vesicles). Using human brain membranes, saturation studies showed that the differential effects of the modulator were maintained. Thus, the modulator significantly increased only the binding capacity for [ If the SV2A modulator has differential effects on the saturation-binding kinetics of the radioligands, then it may be expected to have differential effects on the kinetics of association and dissociation. Previous studies have shown that the association and dissociation rates are fast for both [ 3 H] BRV and [
3 H]LEV; therefore, all binding studies were performed at 4°C. In agreement with previous studies, the association and dissociation of [
3 H]LEV and [ 3 H]BRV were best described by a two-phase model, and the parameters described here are similar to those reported previously under similar assay conditions such as temperature. 3, 4, 21 The significance of these two phases is unknown, particularly in that they are not translated into two apparent affinity states. However, the SV2A protein is a member of the MFS, which has been shown to exist in different conformations, consistent with the alternating transport hypothesis. Of interest, structural evidence from protein-tomography studies has identified the presence of two conformations of the SV2A protein in brain tissue, 27 and homology modeling has suggested differential interaction of LEV analogues with the two distinct conformations of the SV2A protein. 28 For [ 3 H]LEV, the modulator increased the level of specific binding, but it had little effect on the association and dissociation kinetics, consistent with a small effect on the affinity (K d ) for [ 3 H]LEV. In contrast, the modulator had a profound effect on slowing both the association and dissociation of [ 3 H]BRV, consistent with the marked increase in affinity for [ 3 H]BRV. Indeed the marked slowing for [ 3 H]BRV meant that equilibrium would not be reached in the 2-h incubation period, suggesting that this increase in affinity may be underestimated. In the presence of the modulator, the kinetics for association were best described by a one-phase model with kinetics similar to those of the slow component seen in the absence of the modulator. In contrast, two phases were still apparent in the dissociation study with a marked slowing in both off-rates. The kinetic studies therefore confirmed the findings of a differential effect of the modulator on the binding of 3 H]LEV in native tissue was the presence of physiologic levels of expression and physiologic compartments of expression (namely, the synaptic vesicle). In cells that endogenously express secretory vesicles, >90% of the SV2 protein is associated vesicles, 30 and there is a marked (sixfold) enrichment of SV2A binding in synaptic vesicles compared to synaptic membranes. 31 In HEK293 cells, which lack secretory vesicles, much of the expression is intracellular -presumably in endoplasmic reticulum membranes (P. Foerch, UCB Pharma, unpublished observations). It would therefore be interesting to extend these studies to purified vesicular preparations.
Here, we have shown a differential effect of the modulator on the interaction of LEV and BRV with the SV2A protein, suggesting that LEV and BRV act at different binding sites or interact with different conformational states of the SV2A protein. However, despite intensive efforts, the precise function of the SV2A protein remains unknown. There is evidence that the SV2A protein is involved in synaptic vesicle dynamics and neurotransmitter release, but the mechanism of how it contributes to these effects remains elusive. A recent review 20 highlighted some of the differences between BRV and LEV, including in amygdala-kindled mice, where BRV afforded nearly complete seizure suppression (whereas LEV provided only limited protection, even at high doses). It is tempting to speculate that some of these pharmacologic differences may be due to differences in the interaction of BRV and LEV with the SV2A protein. Given that there is a downregulation of the SV2A protein during epileptogenesis and in chronic epilepsy, 32 it would also be interesting to see if the modulation of conformational states and the differential interactions with BRV and LEV were altered in disease states.
